Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Pacific Edge Limited ( (PFGTF) ) just unveiled an announcement.
Pacific Edge Limited has requested a trading halt on its securities as it assesses the implications of a finalized draft Local Coverage Determination by Novitas, concerning the reimbursement of its Cxbladder tests by Medicare. This move is crucial as the company reviews the decision with legal and industry experts and prepares to inform investors, potentially impacting its operations and market positioning.
More about Pacific Edge Limited
Pacific Edge Limited operates in the medical diagnostics industry, primarily focusing on cancer detection. The company is known for its Cxbladder tests, which are designed to help in the non-invasive detection and management of bladder cancer, with a significant market focus on securing reimbursement for its tests from healthcare insurers like Medicare.
YTD Price Performance: -18.57%
Average Trading Volume: 11,620
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $59.53M
See more data about PFGTF stock on TipRanks’ Stock Analysis page.
